Aims: Enrollment criteria vary substantially among cardiovascular outcome trials (CVOTs) of sodium-glucose cotransporter-2 inhibitors (SGLT-2is), which impacts the relationship between a trial population and the general type 2 diabetes (T2D) population. The aim of this study was to evaluate the representativeness of four SGLT-2i CVOTs of a general T2D population.
| INTRODUCTION
Patients with type 2 diabetes are at increased risk of mortality and cardiovascular (CV) disease. 1 Recent cardiovascular outcome trials (CVOTs) have shown clinically important results in reducing CV risk when using sodium-glucose cotransporter-2 inhibitors (SGLT-2is), and further studies are upcoming. [2] [3] [4] [5] [6] The generalizability of the results of clinical trials to common clinical practice is recognized as a major issue. This is often evaluated as external validity of the study as it is important in clinical decision making and in implementation of new clinical guidelines. As enrolment criteria vary among SGLT2-i CVOTs, it is expected that they will have an impact on the external validity of the results. An understanding of external validity is particularly important as the recently updated ADA/EASD position statement concerning glucose-lowering therapy in patients with T2D has strengthened the position of SGLT-2is. 7 Many CVOTs include patients with a high risk of CV and with an expected high rate of CV events, to ensure that differences in CV outcomes may be reported with sufficient statistical power. As a consequence, various degrees of strict CVOT patient enrolment criteria may impact the representativeness of the trial population of a general T2D population and, thus, may also impact the external validity of study results. 8, 9 Four CVOTs that examined treatment with SGLT-2is are within the scope of this study. [3] [4] [5] [6] Major differences exist among these CVOTs concerning inclusion criteria. Two of the trials included only patients with established CV disease (EMPA-REG OUTCOME 5 and VERTIS-CV 10 ), while the other two trials also included patients with additional CV risk factors (DECLARE-TIMI 58, 6 ≥ 2 CV risk factors, and CANVAS, 4 ≥ 3 CV risk factors).
The aim of this analysis was to evaluate the representativeness of four SGLT-2i CVOTs (CANVAS, EMPA-REG OUTCOME, VERTIS-CV, DECLARE-TIMI 58) by applying the respective main inclusion and exclusion criteria to a general T2D population within four European countries.
| MATERIALS AND METHODS

| Data sources
The present study is part of a large-scale diabetes investigation initiative to acquire an understanding of T2D and its treatment with drugs. 11 The unique features of available health care registries and the corresponding secondary data from health care systems (claims data from Germany, electronic health care records data from The Netherlands, full population registry data from Norway and Sweden) were utilized, in order to include all T2D patients who filled prescriptions for glucose-lowering drugs. 11 For a detailed description of data sources, see Online Supplemental Appendix, Section 1.
| Germany
Data from Germany were obtained from the Betriebskrankenkassen were fully anonymized before analyses were performed by TeamGesundheit Gesellschaft für Gesundheitsmanagement mbH, Essen, Germany. All required study approvals were obtained. 
| The Netherlands
| Study population
All patients who were using glucose-lowering drugs within the year prior to 31 December 2015 or during the last quarter of 2015 in Germany, were included (Online Supplemental Appendix 1.2).
| Baseline data
Patient baseline data included characteristics (eg, age and sex), and comorbidities retrieved from all available data prior to and including the index date, with the exception of cancer (within 5 years prior to the index date). Prior medications were defined as any dispensed 12 months (3 months in the Netherlands) prior to and including the index date.
| Inclusion and exclusion criteria
Adaptation of the inclusion and exclusion criteria of the CVOTs to the respective countries' health care data was performed by using detailed diagnostic codes, procedure codes and drug codes (Table S1a-S1d, Online Supplemental Appendix). Criteria were adapted to the codes similarly in all countries. The main difference between the included CVOTs concerns inclusion criteria; the EMPA-REG OUTCOME 5 and VERTIS-CV 3 trials included only patients with established CV disease, while the DECLARE-TIMI 58 16 and CANVAS 4 trials also included patients with CV risk factors only (DECLARE-TIMI 58, ≥2 and CAN-VAS, ≥3).
| Outcome
Representativeness was determined by dividing the number of patients fulfilling the four CVOT key inclusion and exclusion criteria by the total enrolled T2D population.
| Statistical analysis
Demographic data are presented as mean (SD) or n (%). No statistical comparisons were performed among country results. All analyses were conducted using SAS, version 9.4 (SAS Institute Inc., Cary, North Carolina) or R statistical software (R version 3.1.1 or 3.2.3). 17 3 | RESULTS
| Baseline
In total, a T2D population of 803 836 patients was identified in Germany (n = 239 485), in The Netherlands (n = 36 213), in Norway, (n = 149 782) and in Sweden (n = 378 356) ( Table 1 ). The use of metformin was high in all countries (67%-85%). The use of newer oral glucose-lowering drugs (DPP-4i, SGLT-2i and GLP-1RA) was the highest in Germany and Norway, whereas use of sulphonylurea was the highest in The Netherlands and use of insulin was the highest in Sweden. All four populations had similar CV disease profiles at baseline, with a prevalence ranging from 25% in Norway to 44% in Germany. The use of CV preventive drug treatment was similarly high, more than 80%, in all countries.
When comparing the four European T2D populations with the respective CVOT patients (Table 2) , the general T2D patients were slightly older, were more often women, and had less prevalent CV disease.
| Representativeness results
The DECLARE-TIMI 58 trial showed the highest representativeness (59%), followed by the CANVAS (34%), EMPA-REG OUTCOME (21%) and VERTIS-CV (17%) trials (Figure 1 ). Compared to the other CVOTs, representativeness in the DECLARE-TIMI 58 trial was 2-, 3-and 4-fold, respectively. Representativeness results were consistent across all four countries ( Figure 2 and Table S2 , Online Supplemental Appendix).
| Sensitivity analysis
When laboratory data available in the database from The Netherlands were used additionally as inclusion and exclusion criteria, the representativeness compared to the general T2D populations was, in general, lower for all four CVOTs ( Figure S1 , Online Supplemental Appendix). The most important reason for the lower representativeness was the HbA1c inclusion criteria, explained by missing HbA1c data or by HbA1c being outside the defined range. The DECLARE-TIMI 58 trial consistently showed the highest representativeness, but with higher relative differences compared to the primary analysis described above.
| DISCUSSION
In this observational study, we have investigated how four different SGLT-2i CVOT populations, defined by applying main inclusion and exclusion criteria from the respective trials, are representative of general T2D populations in four European countries, Germany, The
Netherlands, Norway and Sweden. We found that the DECLARE-TIMI 58 trial had the highest representativeness, covering approximately 60% of patients in a general T2D population, and this was almost 2-, 3-and 4-fold higher, respectively, as compared to the CANVAS (34%), EMPA-REG OUTCOME (21%) and VERTIS-CV (17%) trials. [3] [4] [5] [6] With only small variations, findings were consistent across all four countries. Similar patterns, but with more pronounced differences among the CVOTs compared to the main findings, were seen when also including laboratory data in the inclusion and exclusion criteria (available in The Netherlands only).
The most important differences among designs of the respective CVOTs are the inclusion criteria determining CV risk at baseline, relevant when using CV outcomes as measures. Here, two of the studies, DECLARE-TIMI 58 and CANVAS, allowed for inclusion of patients without established CV disease, but with multiple CV risk factors, whereas the EMPA-REG OUTCOME and VERTIS-CV studies limited participants to T2D patients with established CV disease. [3] [4] [5] [6] Our results clearly show that the use of less restrictive CV inclusion criteria enhances representativeness, as in the DECLARE-TIMI 58 6 and CAN-VAS 4 trials as compared to the EMPA-REG OUTCOME and VERTIS-CV trials. 
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This analysis is based on registries and therefore carries some limitations relating to the completeness and quality of the registries. Also, there may be differences among the registries from the four countries, and it is not possible to analyse the actual cause of the differences in representativeness as many different criteria seem to interact. For example, differences among countries in age and CV disease at baseline seem to play an important role in explaining the differences in representativeness.
From our analysis, we can determine only which prescriptions were filled, which does not guarantee actual ingestion of the drug.
As such, we have no information on medication adherence once it is picked up from the pharmacy. The present work has limited In conclusion, consistent patterns of representativeness for four cardiovascular outcome trials involving large T2D populations from European countries were found when applying main inclusion and exclusion criteria. In this study, the DECLARE-TIMI 58 trial represented two out of three general T2D patients, and the estimated representativeness was 2-, 3-and 4-fold higher as compared to the CANVAS, EMPA-REG OUTCOME and VERTIS-CV trials, respectively.
This indicates that the DECLARE-TIMI 58 trial included and examined patients who are most representative of the general T2D patient in the studied countries.
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